Skip to main content

Table 3 Multi-centre study of anti-CENP-A antibodies

From: Clinical and serological evaluation of a novel CENP-A peptide based ELISA

 

Berlin

Leuven

Calgary

Neuss

All

SSc

45/126 (35.7%)

30/84 (35.7%)

29/113 (25.7%)

8/11 (72.2%)

112/334 (33.5%)

lSSc

26/52 (50.0%)

26/29 (89.7%)

n.d.

n.d.

52/81 (64.2%)

dSSc

3/26 (11.5%)

3/29 (10.3%)

n.d.

n.d.

6/55 (10.9%)

Controls all

4/120 (3.3%)

9/226 (4.0%)

7/127 (5.5%)

5/321 (1.6%)

25/794 (3.1%)

SLE

4/109 (3.7%)

4/69 (5.8%)

n.d.

1/36 (2.8%)

9/214 (4.2%)

RA

n.d.

0/25 (0.0%)

n.d.

0/15 (0.0%)

0/40 (0.0%)

SjS

0/2 (0.0%)

2/35 (5.7%)

n.d.

0/7 (0.0%)

2/44 (4.6%)

MCTD

0/3 (0.0%)

0/12 (0.0%)

n.d.

0/3 (0.0%)

0/18 (0.0%)

Overlaps

0/4 (0.0%)

0/3 (0.0%)

n.d.

0/9 (0.0%)

0/16 (0%)

PM

n.d.

1/14 (7.1%)

4/28 (8.3%)

0/1 (0.0%)

5/43 (11.6%)

DM

n.d.

1/23 (4.4%)

n.d.

n.d.

1/23 (4.4%)

PBC

n.d.

n.d.

3/51 (5.9%)

0/3 (0.0%)

3/54 (5.6%)

WG

n.d.

n.d.

n.d.

0/3 (0.0%)

0/3 (0.0%)

Others

0/2 (0.0%)

n.d.

n.d.

3/78 (3.9%)

3/80 (4.6%)

CFS

n.d.

0/36 (0.0 %)

n.d.

n.d.

0/36 (0.0%)

CD

n.d.

n.d.

0/48 (0.0%)

n.d.

0/48 (0.0%)

HD

n.d.

1/9 (11.1%)

n.d.

0/166 (0.0%)

1/175 (0.6%)

Sensitivity

35.7%

35.7%

25.7%

n.d.

33.5%

Specificity

96.7%

96.0%

94.5%

98.1

96.9%.

AUC

0.80

0.68

0.42

n.d.

0.67

  1. AUC: area under the curve; CD: Crohn's disease; CFS: chronic fatigue syndrome; DM: dermatomyositis; dSSc: diffuse cutaneous systemic sclerosis; HD: healthy donors, lSSc: limited cutaneous systemic sclerosis; MCTD: mixed connective tissue disease; n.d.: not determined; PBC: primary biliary cirrhosis; PM: polymyositis; RA: rheumatoid arthritis; SjS: Sjögren's syndrome; SLE: systemic lupus erythematosus; SSc: systemic sclerosis; WG: Wegener granulomatosis